Altavant Sciences GmbH clinical trials
Acquired by Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
The registry lists 6 studies whose lead sponsor is Altavant Sciences GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 4, 2025.
Before and after it joined Sumitomo Pharma Co., Ltd.
- First submitted before Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- 1
- First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- 5
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Altavant Sciences GmbH6 studies
Something wrong with this grouping? Tell us on the Sumitomo Pharma Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Sumitomo Pharma Co., Ltd. studies →
- A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)CompletedNCT04712669Phase 2
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the HeartCompletedNCT05933447Phase 1
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and SafetyCompletedNCT05684640Phase 1
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Pharmacokinetics and Excretion of Oral [14C]-Rodatristat EthylCompletedNCT05006118Phase 1
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Multiple-Ascending Dose in Japanese Patients Bridging StudyCompletedNCT05065359Phase 1
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)TerminatedNCT03924154Phase 2
Sponsor listed in the registry: Altavant Sciences GmbH · First submitted before Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.